AAT Deficiency eLearning
Begin eLearning Case Study
Alpha-1 antitrypsin (AAT) deficiency* – which can lead to hereditary emphysema – is a common, easily diagnosed, and effectively managed hereditary disease.1
*Also known as Alpha-1, AAT Deficiency, AATD, A1-PI deficiency, alpha-1 antiprotease deficiency, A1AD, or hereditary or genetic emphysema.
AAT deficiency is more common than cystic fibrosis, spina bifida, Hodgkin's lymphoma, testicular cancer, and cervical cancer. Yet only 5% of AAT deficient patients have been identified.2 Why? In part because symptoms of hereditary emphysema are easily confounded with symptoms of non-hereditary emphysema.
This eLearning session presents a case of a patient with typical symptoms. You may well recognize one or more of your patients in her story. By the end of the case study, you will see the differentiating factors in her symptoms and history, the appropriate timing and testing for AAT, and the options for effective disease management.
Begin eLearning ProgramARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
References
- Adapted from the American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with AAT deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
- Wenker M. Screening for alpha1-PI deficiency in patients with lung diseases. Respir Med. 2000;94(suppl C):S16-17.
